LEQEMBI Concentrate for solution for infusion Ref.[115156] Active ingredients: Lecanemab

Source: European Medicines Agency (EU)  Revision Year: 2025  Publisher: Eisai GmbH, Edmund-Rumpler-Straße 360549 Frankfurt am Main, Germany, e-mail: medinfo_de@eisai.net

Product name and form

LEQEMBI 100 mg/mL concentrate for solution for infusion.

Pharmaceutical Form

Concentrate for solution for infusion.

Clear to slightly opalescent, colourless to pale yellow solution.

The solution has a pH of approximately 5.0 and an osmolality of 350-430 mOsm/kg.

Qualitative and quantitative composition

Each mL of concentrate contains 100 mg of lecanemab.

One vial of 5 mL contains 500 mg of lecanemab (500 mg/5 mL).

One vial of 2 mL contains 200 mg of lecanemab (200 mg/2 mL).

Lecanemab is a recombinant humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody (mAb) produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.

Excipients with known effect:

One 2 mL vial contains 1.0 mg polysorbate 80 (E433).

One 5 mL vial contains 2.5 mg polysorbate 80 (E433).

For the full list of excipients, see section 6.1.

Active Ingredient

Lecanemab is an IgG1 monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta and reduces amyloid beta plaques.

List of Excipients

Histidine (for pH-adjustment)
Histidine hydrochloride monohydrate (for pH-adjustment)
Arginine hydrochloride
Polysorbate 80 (E433)
Water for injections

Pack sizes and marketing

2 mL of concentrate containing 200 mg lecanemab in a 6 mL vial (Type I clear glass), with a stopper (chlorobutyl) and a seal (aluminium) with a dark grey flip-off cap, in a pack size of 1.

5mL of concentrate containing 500 mg lecanemab in a 6 mL vial (Type I clear glass), with a stopper (chlorobutyl) and a seal (aluminium) with a white flip-off cap, in a pack size of 1.

Each carton contains one vial.

Not all pack sizes may be marketed.

Marketing authorization holder

Eisai GmbH, Edmund-Rumpler-Straße 360549 Frankfurt am Main, Germany, e-mail: medinfo_de@eisai.net

Marketing authorization dates and numbers

EU/1/24/1891/001
EU/1/24/1891/002

Drugs

Drug Countries
LEQEMBI Lithuania, United States

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.